Skip to main content
SpringerLink
Log in

MicroRNAs and Their Clinical Impact on Resistance to Anticancer Treatment

  • Chapter
  • First Online:
MicroRNAs: Key Regulators of Oncogenesis

Abstract

The clinical use of microRNAs (miRNAs) as diagnostic tools for example for tumor classification or as prognostic markers is becoming increasingly established. In addition, recent studies demonstrated that miRNAs could be used as new therapeutic approach in anticancer treatment including the highly interesting aspect that is regulated by miRNAs: resistance to chemo- and radiotherapy. This chapter aims to elucidate the impact of miRNAs on drug resistance from a clinical point of view, and to highlight their potential role as predictors or modifiers of resistance towards chemotherapeutics and radiotherapy. Therefore, we selected exemplary two different tumor types that present either high or low resistance to chemotherapeutic treatment: esophageal cancer (highly therapy resistant tumor) and ovarian cancer (quite therapy sensitive tumor).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Allegra A, Alonci A, Campo S, Penna G, Petrunago A, Gerace D et al (2012) Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol 41(6):1897–1912

    CAS  PubMed  Google Scholar 

  • Asakura T, Ohkawa K (2004) Chemotherapeutic agents that induce mitochondrial apoptosis. Curr Cancer Drug Targets 4(7):577–590

    Article  CAS  PubMed  Google Scholar 

  • Ballesta A, Lopez J, Popgeorgiev N, Gonzalo P, Doumic M, Gillet G (2013) Data-driven modeling of SRC control on the mitochondrial pathway of apoptosis: implication for anticancer therapy optimization. PLoS Comput Biol 9(4):e1003011

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Blower PE, Verducci JS, Lin S, Park JK, Dai Z, Liu CG et al (2007) MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther 6(5):1483–1491

    Article  CAS  PubMed  Google Scholar 

  • Boyerinas B, Park SM, Murmann AE, Gwin K, Montag AG, Zillhardt M et al (2012) Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer 130(8):1787–1797

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Cai EH, Gao YX, Wei ZZ, Chen WY, Yu P, Li K (2012) Serum miR-21 expression in human esophageal squamous cell carcinomas. Asian Pac J Cancer Prev 13(4):1563–1567

    Article  PubMed  Google Scholar 

  • Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S et al (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 101(9):2999–3004

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Chang H, Zhou X, Wang ZN, Song YX, Zhao F, Gao P et al (2012) Increased expression of miR-148b in ovarian carcinoma and its clinical significance. Mol Med Rep 5(5):1277–1280

    CAS  PubMed  Google Scholar 

  • Chen F, Chen C, Yang S, Gong W, Wang Y, Cianflone K et al (2012) Let-7b inhibits human cancer phenotype by targeting cytochrome P450 epoxygenase 2 J2. PLoS One 7(6):e39197

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Chen MF, Chen PT, Lu MS, Lin PY, Chen WC, Lee KD (2013) IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus. Mol Cancer 12:26

    Article  PubMed Central  PubMed  Google Scholar 

  • Cochrane DR, Howe EN, Spoelstra NS, Richer JK (2010) Loss of miR-200c: a marker of aggressiveness and chemoresistance in female reproductive cancers. J Oncol 2010:821717

    Article  PubMed Central  PubMed  Google Scholar 

  • Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK (2009) MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 8(5):1055–1066

    Article  CAS  PubMed  Google Scholar 

  • Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA (2011) MicroRNAs in body fluids–the mix of hormones and biomarkers. Nat Rev Clin Oncol 8(8):467–477

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Courrech Staal EF, Aleman BM, Boot H, van Velthuysen ML, van Tinteren H, van Sandick JW (2010) Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. Br J Surg 97(10):1482–1496

    Article  CAS  PubMed  Google Scholar 

  • Duursma AM, Kedde M, Schrier M, le Sage C, Agami R (2009) miR-148 targets human DNMT3b protein coding region. RNA 14(5):872–877

    Article  Google Scholar 

  • Eitan R, Kushnir M, Lithwick-Yanai G, David MB, Hoshen M, Glezerman M et al (2009) Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol Oncol 114(2):253–259

    Article  CAS  PubMed  Google Scholar 

  • Esquela-Kerscher A, Slack FJ (2006) Oncomirs – microRNAs with a role in cancer. Nat Rev Cancer 6(4):259–269

    Article  CAS  PubMed  Google Scholar 

  • Fang Y, Fang D, Hu J (2012) MicroRNA and its roles in esophageal cancer. Med Sci Monit 18(3):RA22–RA30

    Article  CAS  PubMed  Google Scholar 

  • Fiorica F, Di Bona D, Schepis F, Licata A, Shahied L, Venturi A et al (2004) Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 53(7):925–930

    Article  CAS  PubMed  Google Scholar 

  • Frederick P, Green H, Huang J, Egger M, Frieboes H, Grizzle W et al (2013) Chemoresistance in ovarian cancer linked to expression of microRNAs. Biotech Histochem 88(7):403–409

    Article  CAS  PubMed  Google Scholar 

  • Fujita Y, Kojima K, Ohhashi R, Hamada N, Nozawa Y, Kitamoto A et al (2010) MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem 285(25):19076–19084

    Article  CAS  PubMed  Google Scholar 

  • Hamano R, Miyata H, Yamasaki M, Kurokawa Y, Hara J, Moon JH et al (2011) Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res 17(9):3029–3038

    Article  CAS  PubMed  Google Scholar 

  • Hong L, Han Y, Zhang H, Li M, Gong T, Sun L et al (2010) The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg 251(6):1056–1063

    Article  PubMed  Google Scholar 

  • Hong F, Li Y, Xu Y, Zhu L (2013) Prognostic significance of serum microRNA-221 expression in human epithelial ovarian cancer. J Int Med Res 41(1):64–71

    Article  CAS  PubMed  Google Scholar 

  • Hu X, Macdonald DM, Huettner PC, Feng Z, El Naqa IM, Schwarz JK et al (2009) A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol 114(3):457–464

    Article  CAS  PubMed  Google Scholar 

  • Huh JH, Kim TH, Kim K, Song JA, Jung YJ, Jeong JY et al (2013) Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer. Br J Cancer 109(2):452–461

    Article  CAS  PubMed  Google Scholar 

  • Hummel R, Hussey DJ, Michael MZ, Haier J, Bruewer M, Senninger N et al (2011a) MiRNAs and their association with locoregional staging and survival following surgery for esophageal carcinoma. Ann Surg Oncol 18(1):253–260

    Article  PubMed  Google Scholar 

  • Hummel R, Wang T, Watson DI, Michael MZ, Van der Hoek M, Haier J et al (2011b) Chemotherapy-induced modification of microRNA expression in esophageal cancer. Oncol Rep 26(4):1011–1017

    CAS  PubMed  Google Scholar 

  • Iliopoulos D, Hirsch HA, Struhl K (2009) An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 139(4):693–706

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Imanaka Y, Tsuchiya S, Sato F, Shimada Y, Shimizu K, Tsujimoto G (2011) MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma. J Hum Genet 56(4):270–276

    Article  CAS  PubMed  Google Scholar 

  • Iorio MV, Croce CM (2012) MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 4(3):143–159

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P et al (2007) MicroRNA signatures in human ovarian cancer. Cancer Res 67(18):8699–8707

    Article  CAS  PubMed  Google Scholar 

  • Kang MH, Reynolds CP (2009) Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 15(4):1126–1132

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Kim T, Reitmair A (2013) Non-coding RNAs: functional aspects and diagnostic utility in oncology. Int J Mol Sci 14(3):4934–4968

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Ko MA, Zehong G, Virtanen C, Guindi M, Waddell TK, Keshavjee S et al (2012) MicroRNA expression profiling of esophageal cancer before and after induction chemoradiotherapy. Ann Thorac Surg 94(4):1094–1102

    Article  PubMed  Google Scholar 

  • Komatsu S, Ichikawa D, Takeshita H, Konishi H, Nagata H, Hirajima S et al (2012) Prognostic impact of circulating miR-21 and miR-375 in plasma of patients with esophageal squamous cell carcinoma. Expert Opin Biol Ther 12(Suppl 1):53–59

    Article  Google Scholar 

  • Komatsu S, Ichikawa D, Takeshita H, Tsujiura M, Morimura R, Nagata H et al (2011) Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer 105(1):104–111

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Kong F, Sun C, Wang Z, Han L, Weng D, Lu Y, Chen G (2011) miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1. J Huazhong Univ Sci Technolog Med Sci 31(4):543–549

    Article  CAS  PubMed  Google Scholar 

  • Kozomara A, Griffith-Jones S (2011) miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 39(Database issue):D152–D157

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Kumar S, Kumar A, Shah PP, Rai SN, Panguluri SK, Kakar SS (2011) MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines. J Ovarian Res 4(1):17

    Article  PubMed Central  PubMed  Google Scholar 

  • Kurashige J, Kamohara H, Watanabe M, Tanaka Y, Kinoshita K, Saito S et al (2012) Serum microRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma. J Surg Oncol 106(2):188–192

    Article  CAS  PubMed  Google Scholar 

  • Lee H, Park CS, Deftereos G, Morihara J, Stern JE, Hawes SE et al (2012) MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features. World J Surg Oncol 10:174

    Article  PubMed Central  PubMed  Google Scholar 

  • Leskelä S, Leandro-García LJ, Mendiola M, Barriuso J, Inglada-Pérez L, Muñoz I et al (2010) The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer 18(1):85–95

    Article  PubMed  Google Scholar 

  • Li H, Yang BB (2013) Friend or foe: the role of microRNA in chemotherapy resistance. Acta Pharmacol Sin 34(7):870–879

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Lin RJ, Xiao DW, Liao LD, Chen T, Xie ZF, Huang WZ et al (2012) MiR-142-3p as a potential prognostic biomarker for esophageal squamous cell carcinoma. J Surg Oncol 105(2):175–182

    Article  CAS  PubMed  Google Scholar 

  • Liu R, Liao J, Yang M, Shi Y, Peng Y, Wang Y, Pan E et al (2012a) Circulating miR-155 expression in plasma: a potential biomarker for early diagnosis of esophageal cancer in humans. J Toxicol Environ Health A 75(18):1154–1162

    Article  CAS  PubMed  Google Scholar 

  • Liu S, Fang Y, Shen H, Xu W, Li H (2012b) Berberine sensitizes ovarian cancer cells to cisplatin through miR-21/PDCD4 axis. Acta Biochim Biophys Sin (shanghai) 45(9):756–762

    Article  Google Scholar 

  • Liu S, Fang Y, Shen H, Xu W, Li H (2013) Berberine sensitizes ovarian cancer cells to cisplatin through miR-21/PDCD4 axis. Acta Biochim Biophys Sin (Shanghai) 45(9):756–762

    Article  CAS  Google Scholar 

  • Lu L, Schwartz P, Scarampi L, Rutherford T, Canuto EM, Yu H et al (2011) MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management. Gynecol Oncol 122(2):366–371

    Article  CAS  PubMed  Google Scholar 

  • Lynam-Lennon N, Reynolds JV, Marignol L, Sheils OM, Pidgeon GP, Maher SG (2012) MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma. J Mol Med 90(12):1449–1458

    Article  CAS  PubMed  Google Scholar 

  • Marchini S, Cavalieri D, Fruscio R, Calura E, Garavaglia D, Nerini IF et al (2011) Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol 12(3):273–285

    Article  CAS  PubMed  Google Scholar 

  • Mariani M, Shahabi S, Sieber S, Scambia G, Ferlini C (2011) Class III β-tubulin (TUBB3): more than a biomarker in solid tumors? Curr Mol Med 11(9):726–731

    Article  CAS  PubMed  Google Scholar 

  • Mateescu B, Batista L, Cardon M, Gruosso T, de Feraudy Y, Mariani O et al (2011) MiR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med 17(12):1627–1635

    Article  CAS  PubMed  Google Scholar 

  • Merkerova M, Vasikova A, Belickova M, Bruchova H (2010) Micro-RNA expression profiles in umbilical cord blood cell lineages. Stem Cells Dev 19(1):17–26

    Article  CAS  PubMed  Google Scholar 

  • Mitamura T, Watari H, Wang L, Kanno H, Hassan MK, Miyazaki M et al (2013) Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET. Oncogenesis 2(3):e40

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Mo MH, Chen L, Fu Y, Wang W, Fu SW (2012) Cell-free circulating miRNA biomarkers in cancer. J Cancer 3:432–448

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Moss C, Kaye SB (2002) Ovarian cancer: progress and continuing controversies in management. Eur J Cancer 38(13):1701–1707

    Article  PubMed  Google Scholar 

  • Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH et al (2008) MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 14(9):2690–2695

    Article  CAS  PubMed  Google Scholar 

  • Odenthal M, Bollschweiler E, Grimminger PP, Schröder W, Brabender J, Drebber U et al (2013) MicroRNA profiling in locally advanced esophageal cancer indicates a high potential of miR-192 in prediction of multimodality therapy response. Int J Cancer 133(10):2454–2463

    Article  CAS  PubMed  Google Scholar 

  • Ohkawa K, Asakura T, Aoki K, Shibata S, Minami J, Fujiwara C et al (2004) Establishment and some characteristics of epoxomicin (a proteasome inhibitor) resistant variants of the human squamous cell carcinoma cell line, A431. Int J Oncol 24(2):425–433

    CAS  PubMed  Google Scholar 

  • Ozols RF (2005) Treatment goals in ovarian cancer. Int J Gynecol Cancer 15(Suppl 1):3–11

    Article  PubMed  Google Scholar 

  • Park YT, Jeong JY, Lee MJ, Kim KI, Kim TH, Kwon YD, Lee C et al (2013) MicroRNAs overexpressed in ovarian ALDH1-positive cells are associated with chemoresistance. J Ovarian Res 6(1):18

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Peng DX, Luo M, Qiu LW, He YL, Wang XF (2012) Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer. Oncol Rep 27(4):1238–1244

    CAS  PubMed  Google Scholar 

  • Prislei S, Martinelli E, Mariani M, Raspaglio G, Sieber S, Ferrandina G et al (2013) MiR-200c and HuR in ovarian cancer. BMC Cancer 13:72

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE (2009) The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 112(1):55–59

    Article  CAS  PubMed  Google Scholar 

  • Revilla-Nuin B, Parrilla P, Lozano JJ, de Haro LF, Ortiz A, Martínez C, Munitiz V et al (2013) Predictive value of MicroRNAs in the progression of Barrett esophagus to adenocarcinoma in a long-term follow-up study. Ann Surg 257(5):886–893

    Article  PubMed  Google Scholar 

  • Rosenwald S, Gilad S, Benjamin S (2010) Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin. Mod Pathol 23(6):814–823

    Article  CAS  PubMed  Google Scholar 

  • Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A et al (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12(7):681–692

    Article  PubMed  Google Scholar 

  • Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C (2008) Role of microRNAs in drug-resistant ovarian cells. Gynecol Oncol 111(3):478–486

    Article  CAS  PubMed  Google Scholar 

  • Sugimura K, Miyata H, Tanaka K, Hamano R, Takahashi T, Kurokawa Y et al (2012) Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma. Clin Cancer Res 18(18):5144–5153

    Article  CAS  PubMed  Google Scholar 

  • Takeshita N, Hoshino I, Mori M, Akutsu Y, Hanari N, Yoneyama Y et al (2013) Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Br J Cancer 108(3):644–652

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Urschel JD, Vasan H (2003) A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 185(6):538–543

    Article  PubMed  Google Scholar 

  • van Jaarsveld MT, Helleman J, Berns EM, Wiemer EA (2010) MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol 42(8):1282–1290

    Article  PubMed  Google Scholar 

  • van Jaarsveld MT, Helleman J, Boersma AW, van Kuijk PF, van Ijcken WF, Despierre E (2012) miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene 32(36):4284–4293

    Article  PubMed  Google Scholar 

  • Vecchione A, Belletti B, Lovat F, Volinia S, Chiappetta G, Giglio S et al (2013) A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci 110(24):9845–9850

    Article  CAS  PubMed  Google Scholar 

  • Wang B, Zhang Q (2012) The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J Cancer Res Clin Oncol 138(10):1659–1666

    Article  CAS  PubMed  Google Scholar 

  • Wang Y, Niu XL, Qu Y, Wu J, Zhu YQ, Sun WJ et al (2010) Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett 295(1):110–123

    Article  CAS  PubMed  Google Scholar 

  • Weber JA, Baxter DH, Zhang S (2010) The microRNA spectrum in 12 body fluids. Clin Chem 56(11):1733–1741

    Article  CAS  PubMed  Google Scholar 

  • Wen J, Zheng B, Hu Y, Zhang X, Yang H, Luo KJ et al (2009) Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line. Oncol Rep 22(1):65–71

    CAS  PubMed  Google Scholar 

  • Wu Y, Xiao Y, Ding X, Zhuo Y, Ren P, Zhou C et al (2011) A miR-200b/200c/429-binding site polymorphism in the 3′ untranslated region of the AP-2 α gene is associated with cisplatin resistance. PLoS One 6(12):e29043

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu G et al (2013) MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene. doi: 10.1038/onc.2012.575 [Epub ahead of print]

  • Xiao YF, Yong X, Fan YH, Lü MH, Yang SM, Hu CJ (2013) MicroRNA detection in feces, sputum, pleural effusion and urine: novel tools for cancer screening (Review). Oncol Rep 30(2):535–544

    CAS  PubMed  Google Scholar 

  • Xu YZ, Xi QH, Ge WL, Zhang XQ (2013) Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer. Asian Pac J Cancer Prev 14(2):1057–1060

    Article  PubMed  Google Scholar 

  • Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K et al (2008) MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 68(24):10307–10314

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Yang C, Cai J, Wang Q, Tang H, Cao J, Wu L et al (2012) Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1. Gynecol Oncol 124(2):325–334

    Article  CAS  PubMed  Google Scholar 

  • Ye G, Fu G, Cui S, Zhao S, Bernaudo S, Bai Y et al (2011) MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. J Cell Sci 124(Pt 3):359–368

    Article  CAS  PubMed  Google Scholar 

  • Zaman MS, Maher DM, Khan S, Jaggi M, Chauhan SC (2012) Current status and implications of microRNAs in ovarian cancer diagnosis and therapy. J Ovarian Res 5(1):44

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Zhang C, Wang C, Chen X, Yang C, Li K, Wang J et al (2010) Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin Chem 56(12):1871–1879

    Article  CAS  PubMed  Google Scholar 

  • Zhang T, Wang Q, Zhao D, Cui Y, Cao B, Guo L et al (2011) The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma. Clin Sci 121(10):437–447

    Article  CAS  PubMed  Google Scholar 

  • Zhang T, Zhao D, Wang Q, Yu X, Cui Y, Guo L et al (2012) MicroRNA-1322 regulates ECRG2 allele specifically and acts as a potential biomarker in patients with esophageal squamous cell carcinoma. Mol Carcinog 52(8):581–590

    Article  PubMed  Google Scholar 

  • Zheng ZF, Su HF, Zou Y, Peng Z, Wu SX (2011) Expression profiles of microRNAs in radioresistant esophageal cell line. Zhonghua Yi Xue Za Zhi 91(9):639–642

    CAS  PubMed  Google Scholar 

  • Zhou L, Yang ZX, Song WJ, Li QJ, Yang F, Wang DS et al (2013) MicroRNA-21 regulates the migration and invasion of a stem-like population in hepatocellular carcinoma. Int J Oncol 43(2):661–669

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General and Visceral Surgery, University Hospital Muenster, Muenster, Germany

    Kirsten Lindner & Richard Hummel

  2. Comprehensive Cancer Center Muenster (CCCM), University Hospital Muenster, Muenster, Germany

    Joerg Haier

Authors
  1. Kirsten Lindner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joerg Haier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard Hummel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard Hummel .

Editor information

Editors and Affiliations

  1. Dept. of Molec. Genetics, Fac. of Biological Sciences, Tarbiat Modares University, Tehran, Iran

    Sadegh Babashah

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Lindner, K., Haier, J., Hummel, R. (2014). MicroRNAs and Their Clinical Impact on Resistance to Anticancer Treatment. In: Babashah, S. (eds) MicroRNAs: Key Regulators of Oncogenesis. Springer, Cham. https://doi.org/10.1007/978-3-319-03725-7_15

Download citation

Publish with us

Policies and ethics

Search

Navigation